Change language dansk English suomi svenska

Generate Estimates Confirm Cancel Hide empty rows Show hidden rows DummyText

BIOMODICS ApS Estimate generation in progress, please wait... 0%

Quicksearch from your own companies XBRLDenmark Analyst: XBRLDenmark

Loading... Loading... Loading... Loading...   Loading...

1000.0 Bankruptcy Risk  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Bankruptcy risk for industry   1.2% 1.2% 1.2% 1.2% 1.2% 1.2% 1.2% 1.2%   Bankruptcy risk   1.3% 1.8% 3.8% 7.2% 1.8% 2.3% 7.3% 7.1%   Credit score (0-100)   83 72 51 32 70 63 33 34   Credit rating   A A BBB BBB A BBB BBB BBB   Credit limit (kDKK)   76.0 1.6 0.0 0.0 2.6 0.1 0.0 0.0   How are these values calculated?   View the automatically generated explanation of bankruptcy risk 1000.0 Income statement (kDKK)  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Net sales   0 0 0 0 0 0 0 0   Gross profit   3,909 3,135 1,916 1,253 4,349 2,809 0.0 0.0   EBITDA   1,200 718 -451 -644 2,059 402 0.0 0.0   EBIT   1,037 670 -481 -672 1,999 257 0.0 0.0   Pre-tax profit (PTP)   1,027.5 671.4 -487.2 -701.4 1,951.8 292.7 0.0 0.0   Net earnings   802.4 527.8 -460.8 -680.4 1,674.8 392.1 0.0 0.0   Pre-tax profit without non-rec. items   1,027 671 -487 -701 1,952 293 0.0 0.0     See the entire income statement 1000.0 Balance sheet (kDKK)  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Tangible assets total   119 70.6 40.6 146 587 442 0.0 0.0   Shareholders equity total   2,071 2,099 1,638 958 2,633 3,025 2,945 2,945   Interest-bearing liabilities   85.1 45.5 563 1,334 99.4 608 0.0 0.0   Balance sheet total (assets)   4,901 3,897 2,741 2,985 8,064 6,684 2,945 2,945   Net Debt   -2,076 -1,767 -411 679 -3,341 -2,856 -2,929 -2,929     See the entire balance sheet 1000.0 Volume  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Net sales   0 0 0 0 0 0 0 0   Net sales growth   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Gross profit   3,909 3,135 1,916 1,253 4,349 2,809 0.0 0.0   Gross profit growth   26.1% -19.8% -38.9% -34.6% 247.0% -35.4% -100.0% 0.0%   Employees   4 4 0 3 0 0 0 0   Employee growth %   0.0% 0.0% -100.0% 0.0% -100.0% 0.0% 0.0% 0.0%   Employee expenses   0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0   Balance sheet total (assets)   4,901 3,897 2,741 2,985 8,064 6,684 2,945 2,945   Balance sheet change%   0.9% -20.5% -29.7% 8.9% 170.1% -17.1% -55.9% 0.0%   Added value   1,199.6 718.5 -451.4 -643.8 2,027.3 401.8 0.0 0.0   Added value %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Investments   -278 -97 -44 77 381 -290 -442 0   Net sales trend   0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0   EBIT trend   3.0 4.0 -1.0 -2.0 1.0 2.0 0.0 0.0   1000.0 Profitability  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A EBITDA %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   EBIT %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   EBIT to gross profit (%)   26.5% 21.4% -25.1% -53.6% 46.0% 9.1% 0.0% 0.0%   Net Earnings %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Profit before depreciation and extraordinary items %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Pre tax profit less extraordinaries %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   ROA %   21.4% 15.4% -14.2% -23.1% 36.7% 4.2% 0.0% 0.0%   ROI %   58.3% 31.6% -21.4% -28.4% 78.9% 9.7% 0.0% 0.0%   ROE %   46.7% 25.3% -24.7% -52.4% 93.3% 13.9% 0.0% 0.0%   1000.0 Solidity  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Equity ratio %   66.7% 71.8% 59.8% 32.1% 69.9% 57.8% 100.0% 100.0%   Relative indebtedness %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Relative net indebtedness %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Net int. bear. debt to EBITDA, %   -173.1% -246.0% 91.0% -105.4% -162.2% -710.9% 0.0% 0.0%   Gearing %   4.1% 2.2% 34.4% 139.3% 3.8% 20.1% 0.0% 0.0%   Net interest   0 0 0 0 0 0 0 0   Financing costs %   24.6% 12.6% 5.1% 4.1% 10.7% 4.4% 0.0% 0.0%   1000.0 Liquidity  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Quick Ratio   4.6 4.6 2.5 1.4 6.6 2.8 0.0 0.0   Current Ratio   1.7 2.1 2.5 1.4 1.4 1.7 0.0 0.0   Cash and cash equivalent   2,161.5 1,812.7 973.8 655.6 3,440.0 3,463.7 0.0 0.0   1000.0 Capital use efficiency  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Trade debtors turnover (days)   0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0   Trade creditors turnover (days)   0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0   Current assets / Net sales %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Net working capital   1,906.9 1,976.7 1,597.6 843.4 1,987.3 2,508.0 0.0 0.0   Net working capital %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   1000.0 Employee efficiency  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Net sales / employee   0 0 0 0 0 0 0 0   Added value / employee   300 180 0 -215 0 0 0 0   Employee expenses / employee   0 0 0 0 0 0 0 0   EBITDA / employee   300 180 0 -215 0 0 0 0   EBIT / employee   259 168 0 -224 0 0 0 0   Net earnings / employee   201 132 0 -227 0 0 0 0